Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$16.62 USD

16.62
559,673

-0.30 (-1.77%)

Updated Sep 1, 2026 04:00 PM ET

After-Market: $16.61 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (96 out of 248)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y

by Zacks Equity Research

Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.

Zacks Equity Research

Integra LifeSciences (IART) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Artivion (AORT) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Penumbra (PEN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

DexCom (DXCM) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 30.77% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

by Urmimala Biswas

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

Zacks Equity Research

Accuray (ARAY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 7.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Why Integra (IART) Could Beat Earnings Estimates Again

by Zacks Equity Research

Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.